Factors | Disease specific survival | Local control | Distance metastasis control | Progression-free survival | |||||
---|---|---|---|---|---|---|---|---|---|
N | p | OR | p | OR | p | OR | p | OR | |
Age | |||||||||
≤35 | 30 | Reference | Reference | Reference | Reference | ||||
>35 | 31 | 0.942 | 15.26 | 0.639 | 0.77 | 0.056 | 4.936 | 0.339 | 1.552 |
Gender | |||||||||
Male | 33 | Reference | Reference | Reference | Reference | ||||
Female | 28 | 0.94 | 23.56 | 0.274 | 1.875 | 0.008 | 21.064 | 0.092 | 2.356 |
Tumor site | |||||||||
Lacrimal gland | 36 | Reference | Reference | Reference | Reference | ||||
Lacrimal sac | 10 | 0.987 | 0 | 0.438 | 0.526 | 0.06 | 0.1 | 0.282 | 0.509 |
Inside orbit | 15 | 0.839 | 1.546 | 0.088 | 0.149 | 0.97 | 0 | 0.029 | 0.153 |
Tumor histology | |||||||||
Epithelial | 46 | Reference | Reference | Reference | Reference | ||||
Sarcoma | 14 | 0.969 | 0 | 0.139 | 4.0 | 0.973 | 0 | 0.547 | 1.58 |
Melanoma | 1 | 0.999 | 30.51 | 0.989 | 0 | 0.021 | 83.51 | 0.2222 | 5.01 |
Tumor status | |||||||||
Primary | 50 | Reference | Reference | Reference | Reference | ||||
Recurrence | 11 | 0.283 | 9.542 | 0.832 | 0.795 | 0.489 | 0.445 | 0.6647 | 0.694 |
Radiation course | |||||||||
First course | 58 | Reference | Reference | Reference | Reference | ||||
Re-irradiation | 3 | 0.712 | 0.476 | 0.531 | 2.543 | 0.878 | 0.783 | 0.343 | 2.946 |
Margin status | |||||||||
R0 + R1/close margin | 22 | Reference | Reference | Reference | Reference | ||||
R2/biopsy | 39 | 0.86 | 0.737 | 0.141 | 2.861 | 0.734 | 0.776 | 0.585 | 11.342 |
Median Tumor diameter* | |||||||||
<4 cm | 49 | Reference | Reference | Reference | Reference | ||||
≥ 4 cm | 11 | 0.048 | 28.01 | 0.161 | 2.768 | 0.001 | 25.4406 | 0.041 | 3.532 |
Extension beyond orbit | |||||||||
No | 48 | Reference | Reference | Reference | Reference | ||||
Yes | 13 | 0.946 | 61.91 | 0.56 | 1.598 | 0.046 | 9.744 | 0.187 | 2.319 |